drugset / Trial / NCT01059539

Long-term Safety and Tolerability of Cariprazine for Bipolar I Disorder

NCT01059539

Phase 3 Completed 403 enrolled Forest Laboratories Gedeon Richter Ltd. · collab
NaSingle-groupOpen-labelTreatment

Summary

The objective of this study is to evaluate the long-term safety, tolerability, and pharmacokinetics of cariprazine in patients with bipolar I disorder.

Timeline

Start
2010-02-28
Primary completion
2012-02-29
Completion
2012-02-29

Drugs

EvaluationDrugModalityDoseRoute
Subject Cariprazine Small molecule 3 mg Oral

Indications